Efranat Ltd.

efranat ltd. is developing an immunotherapy treatment approach for cancer, based on a glycoprotein named ef - 022 (globulin component macrophage activating factor). the product and treatment are based on prof. nobuto yamamoto's innovative approach and extended research over the last 30 years. the concept underlying the innovative yamamoto technology is to engage the body's own natural immune system, and harness it to fight disease. it is supported by initial promising results demonstrating the effectiveness of ef - 022 in the treatment of cancer in both animals and humans. aim efranat was established in 2009, based on the groundbreaking scientific discoveries of prof. nobuto yamamoto. efranat's current activities are directed towards bringing the product from the laboratory to the patient. more specifically, the company is focused on refining the process of ef - 022 production and treatment, and obtaining the required approvals for its use as a medicament, in order to promote its